Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × aflibercept × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5 Sarcoma 4 Genitourinary 3 Gastrointestinal 3 Dermatologic 3 Endocrine 2 CNS 2 Thoracic 1 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Head & Neck 1 Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 35 Melphalan 28 Cyclophosphamide 27 Specimen Handling 25 Biopsy 25 Bortezomib 24 Calcium Dobesilate 19 Magnetic Resonance Spectroscopy 18 Lenalidomide 16 Filgrastim 15 fludarabine phosphate 14 Peripheral Blood Stem Cell Transplantation 13 Vincristine 12 Prednisone 12 dexamethasone acetate 10 dexamethasone 21-phosphate 10 auricularum 10 Doxorubicin 10 sargramostim 9 carfilzomib 9 fludarabine 8 Thalidomide 8 Interferon-alpha 7 Cyclosporine 7 Busulfan 7 trametinib 6 ixazomib 6 Rituximab 6 Etoposide 6 X-Rays 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00437034 2021-02-08

Aflibercept for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Terminated

6 enrolled 5 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡